Merck KGAA Taps PDS For Cancer Vaccine Technology
This article was originally published in The Pink Sheet Daily
The German pharma signs a deal with Indiana-based PDS Biotechnology that will use the company’s adjuvant technology to boost its own compounds.
You may also be interested in...
Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.